Maged Shenouda, Director at RELMADA THERAPEUTICS, INC. (RLMD), bought 978 shares at $23.00 ($22K) on 2019-10-21, disclosed to the SEC on 2019-10-21.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| RLMD | BUY | 2025-11-06 | $1.1M | — | Filing → |
| RLMD | BUY | 2025-05-20 | $97K | — | Filing → |
| RLMD | BUY | 2024-09-11 | $207K | — | Filing → |